ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Pneumocystis jiroveci Pneumonia (PJP) in Kidney and Pancreas Transplant Recipients in the Present Era of Routine Post-Transplant Prophylaxis: Risk Factors and Outcomes

N. Garg, M. Jorgenson, M. Birschbach, J. Descourouez, S. Parajuli, B. Astor, A. Djamali, D. Mandelbrot.

University of Wisconsin, Madison.

Meeting: 2018 American Transplant Congress

Abstract number: 442

Keywords: Cytomeglovirus, Fungal infection, Infection, Prophylaxis

Session Information

Session Name: Concurrent Session: Kidney Infectious - Pot-Pourri

Session Type: Concurrent Session

Date: Tuesday, June 5, 2018

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:18pm-3:30pm

Location: Room 608/609

PJP after transplant (TX) is associated with substantial morbidity and mortality. In the present era of universal and routine implementation of PJP prophylaxis (PPX) during the initial 6 to 12 months after TX, usually with trimethoprim-sulfamethoxazole (TMP-SMX), identifying risk factors for its occurrence can help identify patients who remain at increased risk, and therefore are most likely to benefit from ongoing PPX.

At our program, all kidney and/or pancreas TX recipients routinely receive prophylactic TMP-SMX for 12 months after TX. We reviewed 28 recipients who developed PJP any time after TX between 1994 and 2016. For comparison, 3 recipients without PJP matched on time from TX were identified for each case.

Median time to PJP diagnosis was 4.6 years (IQR: 1.4-9.6 years). Three patients developed PJP in the first year after PPX was stopped prematurely due to adverse effects. Recipients who developed PJP were older at time of TX (51.7 vs 46.2 years; p=0.05) and were more likely to be non-Caucasian (25.0 vs 9.5%; p=0.07), have received deceased TX (67.9 vs 52.4%; p=0.15), have higher number of HLA mismatches (82.1 vs 61.9% had ≥3/6, 3 being the median for the entire group; p=0.08), have prior history of BK viremia of at least 1000 copies/mL (21.4 vs 6.0%; p=0.01), CMV viremia (35.7 vs 6.0%; p<0.001), invasive fungal infections (7.1 vs 1.2%; p=0.01) and diarrheal illnesses due to Clostridium difficile or norovirus (10.7 vs 2.4%; p=0.1). T-cell depleting induction use, repeat TX, DGF and rejection rates were similar between the two groups. After multivariable adjustment, prior history of CMV viremia (odds ratio [OR] 6.5; p=0.001) and of invasive fungal infections (OR 2.6, p=0.006) remained significantly associated with subsequent diagnosis of PJP. PJP was associated with high mortality (32.1%) and worse graft survival (p=<0.001).

We recommend continuation or re-initiation of PJP PPX after the first year for kidney and pancreas TX recipients if their course is complicated by CMV viremia or invasive fungal infections.

CITATION INFORMATION: Garg N., Jorgenson M., Birschbach M., Descourouez J., Parajuli S., Astor B., Djamali A., Mandelbrot D. Pneumocystis jiroveci Pneumonia (PJP) in Kidney and Pancreas Transplant Recipients in the Present Era of Routine Post-Transplant Prophylaxis: Risk Factors and Outcomes Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Garg N, Jorgenson M, Birschbach M, Descourouez J, Parajuli S, Astor B, Djamali A, Mandelbrot D. Pneumocystis jiroveci Pneumonia (PJP) in Kidney and Pancreas Transplant Recipients in the Present Era of Routine Post-Transplant Prophylaxis: Risk Factors and Outcomes [abstract]. https://atcmeetingabstracts.com/abstract/pneumocystis-jiroveci-pneumonia-pjp-in-kidney-and-pancreas-transplant-recipients-in-the-present-era-of-routine-post-transplant-prophylaxis-risk-factors-and-outcomes/. Accessed May 23, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences